Prediction Augmented Screening Initiative for Lung Cancer

This study aims to improve lung cancer screening (LCS) rates, especially for Veterans, by testing new tools for doctors and clinics. Lung cancer is often found too late, but screening can catch it early when it's curable. Currently, only 20% of eligible Veterans get screened. This study will use "PCP-Facing Tools" for primary care providers (PCPs) and "LCS team population management tools" for clinic staff. These tools help identify Veterans who would benefit most from screening and provide personalized information. The study is looking for Veterans aged 50 to 80 who are assigned to a PCP at a participating site and meet current LCS guidelines. Success will be measured by how many high-benefit Veterans receive a low-dose CT (LDCT) scan for screening. The study status is currently unclear.

Study design: This is an interventional study with a planned enrollment of 23,520 participants. It is testing different tools to improve lung cancer screening.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Participants will be followed from the time the intervention is activated at their facility until they receive an LDCT scan, up to 169 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Prediction Augmented Screening Initiative

Recruiting

NAAges 50–80InterventionalScreening

VA Office of Research and Development

~23,520 participants

Updated 2026-06-26 on ClinicalTrials.gov

What's tested:PCP-Facing ToolsLCS team population management tools

At a glance

Recruiting sites

1 of 4 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

LDCT receipt in high-benefit Veterans

Measured over From time of intervention activation at the facility to the receipt of LDCT scan up to 169 weeks

Conditions

Lung Cancer

Lung Cancer Screening

Where it's being run

4 sites across 3 states

Massachusetts2

Michigan1

South Carolina1

Study leadership

Nichole T Tanner, MD MS BS · PRINCIPAL_INVESTIGATOR · Ralph H. Johnson VA Medical Center, Charleston, SC

Who to contact

Nichole T Tanner, MD MS BS

[email protected]

(843) 789-7341

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

meeting USPSTF eligibility criteria for LCS, as currently encoded in the background logic of LCS clinical reminders maintained by the VA National Center for Lung Cancer Screening (i.e., age 50-80 years; smoked 20 pack-years; current smoking or quit \<15 years ago) OR

predicted benefit calculated using LYFS-CTVA model exceeds a stringent high-benefit threshold of life-year gains with annual LCS, as recommended in the 2021 CHEST LCS guidelines

Exclusion

Veterans who have previously undergone lung cancer screening, are diagnosed with lung cancer, or who do not meet eligibility criteria outlined above

What this trial measures

LDCT receipt in high-benefit VeteransFrom time of intervention activation at the facility to the receipt of LDCT scan up to 169 weeks
The probability of completion of an initial LDCT scan among eligible subjects defined as high-benefit during each quarter of the study (quarter assigned by date of the LDCT order as this event is most proximal to the LCS decision; passage of time between order and scan completion could lead to erroneous attribution of primary outcome to the wrong study phase if scan date is used)

Trialytics